Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
561-580 of 3,900 trials

Hip Replacement Pain Management: Néfopam Study

We are studying the effects of néfopam on pain relief after hip replacement surgery. This trial compares its use against a placebo to see if it helps reduce the need for morphine and improves recovery.

Hip Replacement Surgery6-12 monthsConfirmation phase (III)Standard MedicinesInternal MedicineOrthopedics and Traumatology

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Primary Biliary Cholangitis: Bezafibrate Treatments

We are studying the effects of two doses of bezafibrate in patients with primary biliary cholangitis who aren't responding well to current therapy. The goal is to see if these treatments can improve symptoms and liver health.

Primary Biliary Cholangitis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesGastroenterologyHepatology

Nicotinamide for Liver Fibrosis in Type 2 Diabetes

We are studying whether nicotinamide can help slow liver fibrosis in people with type 2 diabetes. The trial will also assess safety and other health factors related to obesity.

Hepatic Fibrosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDiabetologyEndocrinologyHepatology

Hunter Syndrome: Long-Term Safety of Idursulfase-IT and Elaprase®

We are studying the long-term safety of a treatment combining intrathecal idursulfase-IT and intravenous Elaprase® for individuals with Hunter syndrome and cognitive impairment. This research aims to ensure the safety of these therapies over time.

Hunter's SyndromeConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyInternal MedicineNeurology

Fibrodysplasia Ossificans Progressiva: INCB000928 Study

We are testing a new medication, INCB000928, to see if it can prevent new bone growth in people with Fibrodysplasia Ossificans Progressiva. The study will also evaluate the safety and tolerability of this treatment.

Fibrodysplasia Ossificans Progressiva>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Breast Cancer: Stopping CDK4/6 Inhibitors

We are studying whether stopping CDK4/6 inhibitors helps maintain disease stability in patients with metastatic HR positive, HER2 negative breast cancer. This trial involves patients who have had stable disease after long-term treatment.

Metastatic HR Positive, HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Chronic Pancreatitis: Metamizole for Pain Relief

We are investigating whether adding metamizole to existing pain treatments helps reduce pain in patients with chronic pancreatitis diagnosed within the last three years.

Chronic Pancreatitis1-2 yearsMonitoring phase (IV)Standard MedicinesGastroenterologyInternal Medicine

Esophageal Cancer: Preventing Infections After Surgery

We are studying whether a special treatment can reduce the risk of pneumonia and other infections in patients undergoing surgery for esophageal cancer. This may help improve recovery and overall health after the procedure.

Esophageal Cancer3-6 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesGastroenterologyInfectious DiseasesOncologyPulmonology

HER2-Negative Breast Cancer: Pembrolizumab and Radiation Therapy

We are studying a new treatment combining immunotherapy and radiation for patients with HER2-negative breast cancer who haven't responded to initial chemotherapy. The goal is to see if this approach improves cancer response and quality of life.

HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)Standard MedicinesOncology

Alpelisib for Lymphatic Malformations with PIK3CA Mutation

We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.

Lymphangioma>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Endometrial Cancer: NEPA for Nausea Relief

We are studying whether a single dose of NEPA can effectively prevent nausea and vomiting in patients with endometrial cancer receiving chemotherapy. This trial also assesses the safety of NEPA and its effects on patients' quality of life.

Chemotherapy-Induced Nausea and Vomiting Prophylaxis≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncology

Alzheimer's Disease: KarXT Medication Study

We are examining how well the medication KarXT is tolerated over a long period in people with psychosis related to Alzheimer's disease. This study aims to ensure the safety of this treatment for participants.

Psychosis Associated with Alzheimer's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Nipocalimab for Generalized Myasthenia Gravis

We are studying whether nipocalimab IV infusions can help adults with generalized myasthenia gravis perform daily activities better than a placebo. This research aims to assess its effectiveness and safety.

Myasthenia Gravis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Advanced Ovarian Cancer: Comparing Treatment Combinations

We are studying two different drug combinations to see which one helps patients with advanced ovarian cancer live longer without disease progression after surgery. This trial involves patients who have undergone complete initial surgery.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Atopic Eczema: Dupilumab Dosing Study

We are studying how different dosing schedules of dupilumab affect people with controlled atopic eczema. The goal is to see which schedule works best for managing symptoms and improving quality of life.

Atopic Eczema3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Advanced Breast Cancer: Saruparib and Camizestrant Study

We are studying a new combination treatment for adults with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if it helps patients live longer without disease progression compared to standard therapies.

Advanced Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Fertility Treatment: Natural Progesterone vs. GnRH Antagonists

We are comparing a natural progesterone treatment to a standard injectable medication for women undergoing ovarian stimulation. The goal is to see which method is more effective and cost-efficient in preventing hormonal surges.

Women Undergoing Ovarian Stimulation for Oocyte DonationMonitoring phase (IV)No PlaceboInvestigational MedicinesGynecology and Obstetrics

Metastatic Melanoma: Diclofenac with PD-1 Inhibitor

We are studying whether adding diclofenac to ongoing PD-1 inhibitor therapy helps patients with metastatic melanoma who have stable disease. This trial aims to evaluate the potential benefits of this combination treatment.

Metastatic Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatologyOncology

Advanced Solid Tumors: T3P-Y058-739 Treatment

We are testing a new genetically-modified bacterium for patients with advanced solid tumors. This study aims to explore its safety and potential benefits in treating cancer.

Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Oncology